Please use this identifier to cite or link to this item:
|Title:||Beware ketoacidosis with SGLT2 inhibitors in latent autoimmune diabetes.|
|Authors:||Nolan, Brendan;Varadarajan, Suresh;Fourlanos, Spiros;Neoh, Sandra L|
|Affiliation:||Department of Endocrinology, Austin Health, Heidelberg, Victoria, Australia|
Department of Diabetes and Endocrinology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia
Department of Endocrinology, Northern Hospital, Epping, Victoria, Australia
|Citation:||The American journal of medicine 2020; online first: 7 January|
|Abstract:||Sodium-glucose co-transporter-2 (SGLT2) inhibitors are increasingly used for the treatment of type 2 diabetes but have been associated with ketoacidosis. We report a case series of three patients with latent autoimmune diabetes who presented with ketoacidosis, including one case with normal blood glucose levels, in the context of SGLT2 inhibitor use. SGLT2 inhibitors should only be used with caution and close clinical monitoring in patients with latent autoimmune diabetes. A clinical risk score permits targeted autoantibody testing and should be undertaken prior to commencement of SGLT2 inhibitors and/or cessation of insulin.|
latent autoimmune diabetes
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.